Previous 10 | Next 10 |
Heat Biologics (HTBX) announces that the latest data from HS-110, the company’s lead product, has been accepted for poster presentation at the 2021 American Society of Clinical Oncology ((ASCO)) Annual Meeting, to be held next month.Shares up more than 12% premarket.HS-110 is...
DURHAM, N.C., May 20, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that the latest data from HS-110, the Company’s lead product, h...
DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that PTX-35 will be featured in several presentations and panel discus...
This is not EF Hutton, but it could be more #powerful. A picture speaks a thousand words, they say, and the #priceaction of Heat Biologics Inc (NASDAQ: HTBX) tells an important story. The movement tells us where investors perceive value, or the lack of it, and if we pay atte...
Heat Biologics ([[HTBX]] -1.8%) announces the appointment of Anthony Manning as the company's chief scientific advisor.Manning will be responsible for strategic initiatives to accelerate the development of Heat Biologics’ product portfolio.He brings over three decades of...
DURHAM, N.C., May 10, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, tod...
Heat Biologics (HTBX): Q1 GAAP EPS of -$0.31 misses by $0.01.Revenue of $0.54M (-40.0% Y/Y) misses by $0.08M.As of March 31, 2021, the Company had approximately $132 million in cash, cash equivalents and short investments.Shares +3.86% PM.Press Release For further details see: Heat Biol...
DURHAM, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates...
#technicalanalysis provides insights that #fundamentalanalysis cannot. We can use that to our #advantage in Heat Biologics Inc (NASDAQ: HTBX). Using the data offered below we have a real-time example. Review The technical data for HTBX below, and the adde...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you stumbled upon this morning’s more-than-1,000% jump in the price of InspireMD (NYSEMKT: NSPR ) stock on top of an even-bigger gain on Monday, allow us to unpack things for you. Today’s the day that...
News, Short Squeeze, Breakout and More Instantly...
DURHAM, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) , an integrated contract development and manufacturing organization (CDMO), today announced that it has been awarded a contract in excess of $1 million with an NIH-funded researcher at a ...
DURHAM, N.C., March 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) , an integrated contract development and manufacturing organization (CDMO), today announced that it has been accepted into the Biopharmaceutical Manufacturing Preparedness Consortium (Bio...
DURHAM, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the closing of its previously announced public offer...